EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY 4.0

Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial ( OXB ‐102/Axo‐Lenti‐ PD ) in People with Parkinson's Disease

Simon Rowe, Amy Evans, Saeed Kayhanian, Philip C Buttery, Robert Morris, Katie Andresen, Laura Sherlock, Samuel Hewitt, Tagore Nakornchai, Marwan Hariz, Kyriacos Mitrophanous, Ludvic Zrinzo und 8 weitere

Movement Disorders · 2026

DOI: 10.1002/mds.70378 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Movement Disorders, 2026. Verfasst von Simon Rowe und 19 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Dopamine, Genetic Therapy, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, sponsor: Oxford BioMedica (UK) Ltd; collaborator: Axovant Sciences Ltd, Sponsor: Axovant Sciences Ltd; collaborator: Oxford BioMedica (UK) Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SUNRISE‐PD was a dose‐escalating, phase 1/2 study investigating a second‐generation lentiviral vector gene therapy delivering the genes for dopamine synthesis (OXB‐102) to treat Parkinson's disease (PD). The trial was prematurely terminated due to insolvency of the sponsor.

Objectives

The aim was to provide an investigator‐led description of the clinical course for the 6 patients enrolled in the OXB‐102 trial.

Methods

Individual patient data were extracted, compiled, and summarized from investigator records.

Results

Six patients received a low (n = 2) and a higher (n = 4) dose of the OXB‐102 gene therapy. There were eight serious adverse events (SAE), of which only one was considered definitely related to the intervention. All SAEs were transient and resolved without sequelae. Efficacy data were limited, but some stabilization of motor function was observed in most of the patients.

Conclusion

This novel dopamine gene therapy appears safe in patients with moderate‐to‐severe PD, with some possible stabilizing effects on their clinical course. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DopamineGenetic TherapyParkinson DiseaseAgedFemaleHumansMaleMiddle AgedGene Therapy AgentsGenetic VectorsLentivirusTreatment Outcome

Stichwörter der Autor:innen

Parkinson's diseaseclinical trialgene therapy

Substanzen

Dopamine

Autor:innen und Institutionen

  • Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
  • Department of Clinical Neurosciences and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
  • Department of Neurosurgery, Cambridge University Hospitals, Cambridge, United Kingdom.
  • UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, United Kingdom.
  • Deparment of Clinical Neuroscience, Umeå University, Umeå, Sweden.
  • Oxford Biomedica (UK) Limited, Oxford, United Kingdom.

ORCID-Profile: Thomas Foltynie

Förderung

  • National Institute for Health and Care Research
  • sponsor: Oxford BioMedica (UK) Ltd; collaborator: Axovant Sciences Ltd
  • Sponsor: Axovant Sciences Ltd; collaborator: Oxford BioMedica (UK) Ltd
  • Sponsor: Sio Gene Therapies

Zitieren

APA

Rowe, S., Evans, A., Kayhanian, S., Buttery, P. C., Morris, R., Andresen, K., Sherlock, L., Hewitt, S., Nakornchai, T., Hariz, M., Mitrophanous, K., Zrinzo, L., Appleby, M., Woodgate, P., Maru, S., Limousin, P., Girges, C., Foltynie, T., Palfi, S., & Barker, R. A. (2026). Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial ( OXB ‐102/Axo‐Lenti‐ PD ) in People with Parkinson's Disease. Movement Disorders. https://doi.org/10.1002/mds.70378

Vancouver

Rowe S, Evans A, Kayhanian S, Buttery PC, Morris R, Andresen K, et al. Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial ( OXB ‐102/Axo‐Lenti‐ PD ) in People with Parkinson's Disease. Movement Disorders. 2026. doi:10.1002/mds.70378

BibTeX
@article{Rowe2026,
  author = {Rowe, Simon and Evans, Amy and Kayhanian, Saeed and Buttery, Philip C and Morris, Robert and Andresen, Katie and Sherlock, Laura and Hewitt, Samuel and Nakornchai, Tagore and Hariz, Marwan and Mitrophanous, Kyriacos and Zrinzo, Ludvic and Appleby, Matthew and Woodgate, Phil and Maru, Seema and Limousin, Patricia and Girges, Christine and Foltynie, Thomas and Palfi, Stephane and Barker, Roger A},
  title = {Observations on an Open‐Label Phase 1/2 Dopamine Gene Therapy Trial ( OXB ‐102/Axo‐Lenti‐ PD ) in People with Parkinson's Disease},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70378}
}
Kostenlos starten →